THNR vs. CANC

Last updated Jun 3, 2026

THNR (Amplify Weight Loss Drug & Treatment ETF) and CANC (Tema Oncology ETF) are both Health & Biotech Equities funds. THNR is passively managed, while CANC is actively managed. Over the past year, THNR returned 9.10% vs 49.25% for CANC. A 0.69 correlation means they provide meaningful diversification when combined. THNR charges 0.59%/yr vs 0.75%/yr for CANC.

Performance

THNR vs. CANC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amplify Weight Loss Drug & Treatment ETF (THNR) and Tema Oncology ETF (CANC). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, THNR achieves a -5.20% return, which is significantly lower than CANC's 4.74% return.

THNR

• 1D: -1.47%
• 1M: -2.91%
• YTD: -5.20%
• 6M: -3.73%
• 1Y: 9.10%
• 3Y*: —
• 5Y*: —
• 10Y*: —

CANC

• 1D: -2.40%
• 1M: -2.10%
• YTD: 4.74%
• 6M: 5.93%
• 1Y: 49.25%
• 3Y*: 107.71%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

THNR vs. CANC - Yearly Performance Comparison

	2026 (YTD)	2025	2024
THNR Amplify Weight Loss Drug & Treatment ETF	-5.20%	13.65%	-10.36%
CANC Tema Oncology ETF	4.74%	42.92%	-8.97%

Correlation

The correlation between THNR and CANC is 0.72, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.72
Correlation (All Time) Calculated using the full available price history since May 22, 2024	0.69

The correlation between THNR and CANC has been stable across timeframes, ranging from 0.69 to 0.72 - a consistent structural relationship.

THNR vs. CANC - Sectors Allocation Comparison

Sectors	THNR	CANC
Healthcare	97.7%	100.0%
Financial Services	0.9%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

THNR vs. CANC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

THNR

THNR Risk / Return Rank: 16
THNR Sharpe Ratio Rank: 15
THNR Sortino Ratio Rank: 16
THNR Omega Ratio Rank: 15
THNR Calmar Ratio Rank: 18
THNR Martin Ratio Rank: 17

CANC

CANC Risk / Return Rank: 70
CANC Sharpe Ratio Rank: 63
CANC Sortino Ratio Rank: 65
CANC Omega Ratio Rank: 55
CANC Calmar Ratio Rank: 90
CANC Martin Ratio Rank: 78

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

THNR vs. CANC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amplify Weight Loss Drug & Treatment ETF (THNR) and Tema Oncology ETF (CANC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	THNR	CANC	Difference
Sharpe ratio Return per unit of total volatility	0.48	2.14	-1.66
Sortino ratio Return per unit of downside risk	0.81	3.05	-2.24
Omega ratio Gain probability vs. loss probability	1.10	1.35	-0.25
Calmar ratio Return relative to maximum drawdown	0.76	5.75	-4.99
Martin ratio Return relative to average drawdown	1.75	15.57	-13.82
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

THNR vs. CANC - Sharpe Ratio Comparison

The current THNR Sharpe Ratio is 0.48, which is lower than the CANC Sharpe Ratio of 2.14. The chart below compares the historical Sharpe Ratios of THNR and CANC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	THNR	CANC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.48	2.14	-1.66
Sharpe Ratio (All Time) Calculated using the full available price history	-0.09	-0.04	-0.05

Drawdowns

THNR vs. CANC - Drawdown Comparison

The maximum THNR drawdown since its inception was -32.51%, smaller than the maximum CANC drawdown of -97.53%. Use the drawdown chart below to compare losses from any high point for THNR and CANC.

Drawdown Indicators

	THNR	CANC	Difference
Max Drawdown Largest peak-to-trough decline	-32.51%	-97.53%	+65.02%
Max Drawdown (1Y) Largest decline over 1 year	-12.06%	-8.67%	-3.39%
Max Drawdown (3Y) Largest decline over 3 years	—	-30.27%	—
Current Drawdown Current decline from peak	-13.00%	-56.58%	+43.58%
Average Drawdown Average peak-to-trough decline	-12.24%	-73.20%	+60.96%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.26%	3.20%	+2.06%

Volatility

THNR vs. CANC - Volatility Comparison

The current volatility for Amplify Weight Loss Drug & Treatment ETF (THNR) is 5.16%, while Tema Oncology ETF (CANC) has a volatility of 6.55%. This indicates that THNR experiences smaller price fluctuations and is considered to be less risky than CANC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	THNR	CANC	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.16%	6.55%	-1.39%
Volatility (6M) Calculated over the trailing 6-month period	13.55%	16.79%	-3.24%
Volatility (1Y) Calculated over the trailing 1-year period	19.15%	23.11%	-3.96%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	19.37%	280.39%	-261.02%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	19.37%	280.39%	-261.02%

THNR vs. CANC - Expense Ratio Comparison

THNR has a 0.59% expense ratio, which is lower than CANC's 0.75% expense ratio.

Dividends

THNR vs. CANC - Dividend Comparison

THNR's dividend yield for the trailing twelve months is around 1.73%, more than CANC's 0.05% yield.

Position	TTM	2025	2024	2023
CANC Tema Oncology ETF	0.05%	0.06%	3.00%	0.56%
THNR Amplify Weight Loss Drug & Treatment ETF	1.73%	1.64%	0.98%	0.00%

Frequently Asked Questions

Can I hold both THNR and CANC in my portfolio?

THNR and CANC have a correlation of 0.72, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, THNR or CANC?

CANC has higher volatility (6.55%) compared to THNR (5.16%). In terms of maximum drawdown, THNR dropped -32.51% vs CANC's -97.53%.

Which ETF is better, THNR or CANC?

On 1-year performance, CANC leads with 49.25% vs 9.10% for THNR. On fees, THNR is cheaper at 0.59% per year. On volatility, THNR has been the lower-risk option at 5.16%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, THNR or CANC?

Over the 1-year period, CANC has performed better with a 49.25% return vs 9.10%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, THNR or CANC?

THNR is cheaper with a 0.59% expense ratio, compared with 0.75% for CANC.

Which ETF pays a higher dividend yield, THNR or CANC?

THNR has the higher dividend yield at 1.73%, compared with 0.05% for CANC.

What is the main difference between THNR and CANC?

They also come from different issuers: Amplify and Tema. Their fees differ too: 0.59% for THNR and 0.75% for CANC.

Which has better risk-adjusted returns?

CANC currently has the higher Sharpe Ratio (2.14 vs 0.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.